A new method for the quantification of antibodies in the enzyme-linked immunosorbent assay is described. This procedure replaces titer determinations based on end-point dilution of the antibody under investigation. Here, the sample is tested in a single dilution and the optical density (OD) obtained is used in the equation log10 titer = alpha.OD beta. The titer can then be calculated by inserting into the formula the values for the constants alpha and beta, which are specified by the manufacturer for each separate batch of kit reagents. This so-called alpha-method saves time and reagents while providing results which are equal to the titration method in accuracy and superior in precision. The alpha-method is also a simpler and reliable alternative to the use of standard or reference curves for the quantification of the antibodies in I.U./ml.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jcla.1860060614 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
"Small is beautiful" - Examining reliable determination of low-abundant therapeutic antibody glycovariants.
J Pharm Anal
October 2024
Department of Biosciences and Medical Biology, Bioanalytical Research Labs, University of Salzburg, Salzburg, 5020, Austria.
Glycans associated with biopharmaceutical drugs play crucial roles in drug safety and efficacy, and therefore, their reliable detection and quantification is essential. Our study introduces a multi-level quantification approach for glycosylation analysis in monoclonal antibodies (mAbs), focusing on minor abundant glycovariants. Mass spectrometric data is evaluated mainly employing open-source software tools.
View Article and Find Full Text PDFChallenges and Insights in Absolute Quantification of Recombinant Therapeutic Antibodies by Mass Spectrometry: An Introductory Review.
Antibodies (Basel)
January 2025
Federal Institute of Material Testing and Research (BAM), 12489 Berlin, Germany.
This review describes mass spectrometry (MS)-based approaches for the absolute quantification of therapeutic monoclonal antibodies (mAbs), focusing on technical challenges in sample treatment and calibration. Therapeutic mAbs are crucial for treating cancer and inflammatory, infectious, and autoimmune diseases. We trace their development from hybridoma technology and the first murine mAbs in 1975 to today's chimeric and fully human mAbs.
View Article and Find Full Text PDFDistinct subcellular localization of tau and alpha-synuclein in lewy body disease.
Acta Neuropathol Commun
January 2025
Center for Neurodegeneration and Experimental Therapeutics, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
Lewy bodies and neurofibrillary tangles, composed of α-synuclein (α-syn) and tau, respectively, often are found together in the same brain and correlate with worsening cognition. Human postmortem studies show colocalization of α-syn and tau occurs in Lewy bodies, but with limited effort to quantify colocalization. In this study, postmortem middle temporal gyrus tissue from decedents (n = 9) without temporal lobe disease (control) or with Lewy body disease (LBD) was immunofluorescently labeled with antibodies to phosphorylated α-syn (p-α-syn), tau phosphorylated at Ser202/Thr205 (p-tau), or exposure of tau's phosphatase-activating domain (PAD-tau) as a marker of early tau aggregates.
View Article and Find Full Text PDFMOF@Ag/AAB/Au@Ag composite matrix full-dimensional divergence effect-based SERS paper sensor for rapid carbaryl quantification.
Food Chem
January 2025
School of Chemistry and Chemical Engineering, University of Jinan, Jinan 250022, China.
Carbaryl is a broad-spectrum carbamate fungicide that may pose a threat to ecosystems and human health. To prevent and control the harm caused by excessive application of carbaryl, a full-dimensional divergence effect SERS sensor has been constructed. Biodegradable paper chips were used as sensor substrates.
View Article and Find Full Text PDFA novel bioassay reflecting response to immune checkpoint inhibitor therapy in non-small cell lung cancer with malignant pleural effusion.
Transl Lung Cancer Res
December 2024
Division of Pulmonary Medicine, Department of Medicine, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan.
Background: Immune checkpoint inhibitor (ICI) therapy has prolonged the survival of a proportion of patients with advanced non-small cell lung cancer (NSCLC). Histological quantification of programmed cell death-ligand 1 (PD-L1) in tumors is a widely adopted marker for predicting the efficacy of ICI treatment. However, its use in patients with malignant pleural effusion (MPE) is occasionally challenging because of the difficulty of tissue sampling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!